DanielsBS.The role of the glomerular epithelial cell in the mainte-nance of the glomerular filtration barrier. Am J Nephrol. 1993;13:318–23.
2.
MyersBD, GuaschA.Selectivity of the glomerular filtration bar-rier in healthy and nephrotic humans. Am J Nephrol. 1993;13:311–7.
3.
KanwarYS.Biophysiology of glomerular filtration and protein-uria. Lab Invest. 1984;51:7–21.
4.
OtaK, ShikataK, MakinoH.The ultrastructural disruption of the glomerular basement membrane in diabetic nephropathy revealed by “tissue negative staining method.”J Diabetes Complications. 1995;9:285–7.
5.
CaulfieldJP, FarquharMG.Identification and characterization of podocalyxin-the major sialoprotein of the renal glomerular epithelial cell. J Cell Biol. 1984;98:1591.
6.
RodewaldR, KarnovskyMJ.Porous substructure of the glomeru-lar slit diaphragm in the rat and mouse. J Cell Biol. 1974;60:423–33.
7.
CybulskyAV, CarbonettoS, HuangQ, . Adhesion of rat glomerular epithelial cells to extracellular matrices: role of 1-integrins. Kidney Int. 1992;42:1099–106.
8.
KaysenGA.Plasma composition in the nephrotic syndrome. Am J Nephrol. 1993;13:347–59.
9.
AppelGB, BlumCB, ChienS, KunisCL, AppelAS.The hyper-lipidemia of the nephrotic syndrome. N Engl J Med. 1985;312:1544–8.
10.
KaysenGA.Nonrenal complications of the nephrotic syndrome. Annu Rev Med. 1994;45:201–10.
11.
BernardDB.Extrarenal complications of the nephrotic syn-drome. Kidney Int. 1988;33:1184–202.
12.
OgiM, YokoyamaH, TomosugiN, HisadaS, OhtaM, TakanedaT, WadaT, NaitoK, IkedaS, GoshimaK, TakasawaK, KobayashiK.Risk factors for infection and immunoglobulin replacement therapy in adult nephrotic syndrome. Am J Kidney Dis. 1994;24:427–36.
13.
Kees-FoltsD, DiamondJR. Relationship between hyperlipi-demia, lipid mediators, and progressive glomerulosclerosis in the nephrotic syndrome. Am J Nephrol. 1993;13:365–75.
14.
FahalIH, McClellandP, HayCR, BellGM.Arterial thrombosis in the nephrotic syndrome. Postgrad Med J. 1994;70:905–9.
15.
GuglerR, ShoemanDW, HuffmanDH, CohlmiaJB, AzarnoffDL.Pharmacokinetics of drugs in patients with the nephrotic syndrome. J Clin Invest. 1975;55:1182–9.
16.
VrhovacB, SarapaN, BakranI, HuicV, Macolic-SarinicV, FranceticI, Wolf-CopordaA, PlavsicF.Pharmacokinetic changes in patients with oedema. Clin Pharmacokinet. 1995;28:405–18.
17.
BernardDB, AlexanderEA.Edema formation in the nephrotic syndrome: pathophysiologic mechanisms. Cardiovascular Medicine. 1979;4:605–25.
18.
ValentinJP, QiuC, MuldowneyWP, YingW, GardnerDG, HumphreysMH.Cellular basis for blunted volume expansion natriuresis in experimental nephrotic syndrome. J Clin Invest. 1992;90:1302–12.
19.
MartinPY, SchrierRW.Renal sodium excretion and edematous disorders. Endocrinol Metab Clin North Am. 1995;24:459–79.
20.
PericoN, RemuzziG.Renal handling of sodium in the nephrotic syndrome. Am J Nephrol. 1993;13:413–21.
21.
JespersenB, EiskjaerH, MogensenCE, . Reduced natriuretic effects of atrial natriuretic peptide in nephrotic syndrome: a possible role of decreased cyclic guanosine monophosphate. Nephron. 1995;71:44–53.
22.
RabelinkTJ, BijlsmaJA, KoomansHA.Iso-oncotic volume expansion in the nephrotic syndrome. Clin Sci (Colch). 1993;84:627–32.
23.
UedaN, NinomiY, NonodaT.Urine kallikrein excretion in rela-tion to renal sodium handling in minimal change nephrotic syndrome. Clin Nephrol. 1991;36:228–33.
24.
KoomansHA, GeersAB, Dorhout MeesEJ, KortlandtW.Lowered tissue-fluid oncotic pressure protects the blood volume in the nephrotic syndrome. Nephron. 1986;42:317–22.
25.
BansalR, PfeifferSE.Regulated galactolipid synthesis and cell surface expression in Schwann cell line D6P2T. J Neurochem. 1987;49:1902–11.
26.
GandelmanK, PfeifferSE, CarsonJH.Cyclic AMP regulation of PO glycoprotein and myelin basic protein gene expression in semidiffer-entiated peripheral neurinoma cell line D6P2T. Development. 1989;106:389–98.
27.
JolesJA, RabelinkTJ, BraamB, KoomansHA.Plasma volume regulation: defenses against edema formation (with special emphasis on hypoproteinemia). Am J Nephrol. 1993;13:399–412.
28.
IchikawaI, RennkeHG, HoyerJR, BadrF, SchorN, TroyJL.Role for intrarenal mechanisms in the impaired salt excretion of experi-mental nephrotic syndrome. J Clin Invest. 1983;71:91–103.
29.
MakkerSP.Mediators of immune glomerular injury. Am J Nephrol. 1993;13:324–36.
30.
BakerCH, AbelFL.Macroand microcirculatory effects of IL-15. Shock. 1995;4:307–10.
31.
KohanDE.Interleukin-1 regulation of collecting duct prostaglandin E2 and cyclic nucleotide accumulation. J Lab Clin Med. 1994;123:668–75.
MarkewitzBA, MichaelJR, KohanDE.Cytokine-induced expression of a nitric oxide synthase in rat renal tubule cells. J Clin Invest. 1993;91:2138–43.
34.
LieberthalW, BernardDB.Clinical relevance of the natriuretic peptides in edematous states. Curr Opin Nephrol Hypertens. 1993;2:653–61.
35.
SmithJD, HayslettJP.Reversible renal failure in the nephrotic syndrome. Am J Kidney Dis. 1992;19:201–13.
36.
GalaskeRG, BaldamusCA, StolteH.Plasma protein handling in the rat kidney: micropuncture experiments in the heterologous phase of anti-GBM-nephritis. Pflugers Arch. 1978;375:269–77.
37.
ParkCH, MaackT.Albumin absorption and catabolism by iso-lated perfused proximal convoluted tubules of the rabbit. J Clin Invest. 1984;73:767–78.
38.
RothschildMA, OratzM, SchreiberSS.Albumin synthesis. N Engl J Med. 1972;286:748–57.
39.
KaysenGA, GanbertoglioJ, JimenezI, JonesH, HutchisonFN.Effects of dietary protein intake on albumin homeostasis in nephrotic patients. Kidney Int. 1986;29:572–7.
40.
ShortCD, DurringtonPN, MallickNP, . Serum and urinary high-density lipoproteins in glomerular disease with proteinuria. Kidney Int. 1986;29:1224–8.
41.
GitlinD, JanewayCA, FarrLE.Studies on the metabolism of plasma proteins in the nephrotic syndrome. I. Albumin, gamma-globu-lin, and iron-binding globulin. J Clin Invest. 1956;35:44–56.
42.
SchreinerGE.Prevention of renal disease and conservation of renal function. Am J Kidney Dis. 1990;16:360–6.
43.
ThomasME, SchreinerGF.Contribution of proteinuria to pro-gressive renal injury: consequences of tubular uptake of fatty acid bear-ing albumin. Am J Nephrol. 1993;13:385–98.
44.
BarnessLA, MollGH, JanewayCA.Nephrotic syndrome. I. Natural history of the disease. Pediatrics. 1950;5:486–503.
45.
KrenskyAM, IngelfingerJR, GrupeWE.Peritonitis in childhood nephrotic syndrome. American Journal of Diseases in Childhood. 1982;136:732–6.
46.
SpeckWT, DresdaleSS, McMillanRW.Primary peritonitis and the nephrotic syndrome. Am J Surg. 1974;127:267–9.
47.
WilfertCM, KatzSL.Etiology of bacterial sepsis in nephrotic syndrome 1963-1967. Pediatrics. 1968;42:840–3.
48.
HarrisRC, IsmailN.Extrarenal complications of the nephrotic syndrome. Am J Kidney Dis. 1994;23:477–97.
49.
HeslanJM, LautieJP, IntratorL, BlancC, LagrueG, SobelAT.Impaired IgG synthesis in patients with the nephrotic syndrome. Clin Nephrol. 1982;18:144–7.
SpikaJS, HalseyNA, LeCT, FishAJ, LumGM, LauerBA, SchiffmanG, GiebinkGS.Decline of vaccine-induced antipneumococ-cal antibody in children with nephrotic syndrome. Am J Kidney Dis. 1986;7:466–70.
52.
LaMannaA, PolitoC, FogliaAC, DiToroA, CafaroMR, Del GadoR.Reduced ressponse to HBV vaccination in boys with steroid-sensitive nephrotic syndrome. Pediatr Nephrol. 1992;6:251–3.
53.
SpikaJS, HalseyNA, FishAJ, LumGM, LauerBA, SchiffmanG, GiebinkGS.Serum antibody response to pneumococcal vaccine in children with nephrotic syndrome. Pediatrics. 1982;69:219–23.
54.
WarshawBL, CheckIJ, HymesLC, DiRussoSC.Decreased serum transferrin concentration in children with nephrotic syndrome:effect on lymphocyte proliferation and correlation with serum immunoglobulin levels. Clin Immunol Immunopathol. 1984;33:210–9.
55.
DardenneM, PleauJ, NabarraB, LefrancierP, DerrienM, ChayJ, BachJ.Contribution of zinc and other metals to the biologic activity of the serum thymic factor. Proc Natl Acad Sci USA. 1982;79:5370–3.
56.
LLachF, PapperS, MassrySG.Hypercoagulability, renal vein thrombosis, and other thrombotic complications of the nephrotic syn-drome. Kidney Int. 1985;28:429–39.
57.
CameronJS.Coagulation and thromboembolic complications of the nephrotic syndrome. Adv Nephrol Necker Hosp. 1984;13:75–114.
58.
FuhJL, TengMM, YangWC, LiuHC.Cerebral infarction in young men with nephrotic syndrome. Stroke. 1992;23:295–7.
59.
GanevalD, FischerAM, BarreJ, PertuisetN, DautzenbergMD, JungersP, HouinG.Pharmacokinetics of warfarin in the nephrotic syndrome and effect on vitamin K-dependent clotting factors. Clin Nephrol. 1986;25:75–80.
60.
RostokerG, Durand-ZaleskiI, Petit-PharM, Ben-MaadiA, JazaerliN, RadierC, RashmouniA, MathieuD, VasileN, RossoJ.Prevention of thrombotic complications of the nephrotic syndrome by the low molecular weight heparin enoxaparin. Nephron. 1995;69:20–8.
61.
D'AmicoGD, GentileMG.Treatment of hyperlipidemia in human renal disease. Miner Electrolyte Metab. 1993;19:196–204.
62.
JovenJ, VillabonaC, VilellaE, MasanaL, AlbertiR, VallesM.Abnormalities of lipoprotein metabolism in patients with the nephrotic syndrome. N Engl J Med. 1990;323:579–84.
63.
MulsE, RosseneuM, DaneelsR, SchurgerM, BoelaertJ.Lipoprotein distribution and composition in the human nephrotic syn-drome. Atherosclerosis. 1985;54:225–37.
64.
WannerC, RaderD, BartensW, KramerJ, BrewerHB, SchollmeyerP, WielandH.Elevated plasma lipoprotein (a) in patients with nephrotic syndrome. Ann Intern Med. 1993;119:263–9.
65.
BaxterJH, GoodmanHC, AllenJC.Effects of infusions of serum albumin on serum lipids and lipoproteins in nephrosis. J Clin Invest. 1961;49:490–8.
66.
DaviesRW, StapransI, HutchinsonGN, KaysenGA.Proteinuria, not altered albumin metabolism, affects hyperlipidemia in the nephrotic rat. J Clin Invest. 1990;86:600–5.
67.
FurukawaS, HiranoT, MamoJ, NaganoS, TakahashiT.Catabolic defect of triglyceride is associated with abnormal very-low-density lipoproteins in experimental nephrosis. Metabolism. 1990;39:101–7.
68.
VaziriND, LiangKH.Downregulation of hepatic LDL receptor expression in experimental nephrosis. Kidney Int. 1996;50:887–93.
69.
RosenmanRH, FreidmanM.In vivo studies of the role of albu-min in endogenous and heparin-activated lipemia clearing in nephrotic rats. J Clin Invest. 1957;36:700–10.
70.
KashyapML, SpivastavaLS, HyndBA, BradyD, PerisuttiC, GlueckC, GartsidePO.Apo protein CII and lipoprotein lipase in human nephrotic syndrome. Atherosclerosis. 1980;35:29–40.
71.
StapransI, GaronSJ, HopperJ, FeltsJM.Characterization of glycosaminoglycans in urine from patients with nephrotic syndrome and control subjects and their effects on lipoprotein lipase. Biochim Biophys Acta. 1981;678:414–22.
OrdonezJD, HiattR, KillebrewE, FiremanB.The risk of coro-nary artery disease among patients with the nephrotic syndrome. Kidney Int. 1990;37:243A.
75.
WheelerDC, ChanaRS.Interactions between lipoproteins, glomerular cells, and matrix. Miner Electrolyte Metab. 1993;19:149–64.
76.
GroneEF, AbboudHE, HohneM, WalliAK, GroneHJ, StukerD, RobenekH, WielandE, SeidelD.Actions of lipoproteins in cultured human mesangial cells: modulation by mitogenic vasoconstrictors. Am J Physiol. 1992;263:F686–96.
77.
WassermanJ, SantiagoA, HolthoferH, EpsteinM, SchlondorffD.Interactions of low-density lipoprotein with rat mesangial cells. Kidney Int. 1989;35:1168–74.
78.
NeugartenJ, SchlondorffD.Lipoprotein interactions with glomerular cells and matrix. Contemp Issues In Nephrol. 1991;24:173–206.
79.
MoorheadJF.Lipids and progressive kidney disease. Kidney Int. 1991;39:S35–40.
80.
AppelGB, AppelAS.Lipid-lowering agents in proteinuric dis-eases. Am J Nephrol. 1990;10(1 Suppl):110–5.
81.
D'AmicoG, GentileMG.Pharmacologic and dietary treatment of lipid abnormalities in nephrotic patients. Kidney Int. 1991;393(1 Suppl):S65–9.
82.
GolperTA, IllingworthR, MorrisCD, BennettWM.Lovastatin in the treatment of multifactorial hyperlipidemia associated with protein-uria. Am J Kidney Dis. 1989;13:312–20.
83.
KusterS, MehlsO, SeidelC, RitzE.Blood pressure in minimal change and other types of nephrotic syndrome. Am J Nephrol. 1990;10(1 Suppl):76–80.
84.
RostinM, BartheP, HouinG, AlvinerieM, BouissouF.Pharmacokinetics of prednisolone in children with nephrotic syndrome. Pediatr Nephrol. 1990;4:470–3.
85.
MillerPF, BowmerCJ, WheeldonJ, BrocklebankJT.Pharmacokinetics of prednisolone in children with nephrosis. Arch Dis Child. 1990;65:196–200.
86.
EliasAN, CarreonG, VaziriND, PandianMR, OveisiF.The pituitary-gonadal axis in experimental nephrotic syndrome in male rats. J Lab Clin Med. 1992;120:949–54.
87.
AfrasiabiMA, VaziriND, GwinupG, MaysDM, BartonCH, NessR, ValentaLJ.Thyroid function studies in the nephrotic syndrome. Ann Intern Med. 1979;90:335–8.
88.
VaziriND, KaupkeCJ, BartonCH, GonzalesE.Plasma concen-tration and urinary excretion of erythropoietin in adult nephrotic syn-drome. Am J Med. 1992;92:35–40.
89.
ZhouXJ, VaziriND.Erythropoietin metabolism and pharmaco-kinetics in experimental nephrosis. Am J Physiol. 1992;263:F812–5.
90.
GoldsteinDA, HaldimannB, ShermanD, NormanAW, MassrySG.Vitamin D metabolites and calcium metabolism in patients with nephrotic syndrome and normal renal function. J Clin Endocrinol Metab. 1981;52:116–21.
91.
MallucheHH, GoldsteinDA, MassrySG.Osteomalacia and hyperparathyroid bone disease in patients with nephrotic syndrome. J Clin Invest. 1979;63:494–500.
KhamisehG, VaziriND, OveisiF, AhmadniaMR, AhmadniaL.Vitamin D absorption, plasma concentration, and urinary excretion of 25-hydroxyvitamin D in nephrotic syndrome. Proc Soc Exp Biol Med. 1991;196:210–3.
94.
KoenigKG, LindbergJS, ZerwekhJE, PadalinoPK, CushnerHM, CopleyJB.Free and total 1,25-hydroxyvitamin D levels in subjects with renal disease. Kidney Int. 1992;41:161–5.
95.
MizokuchiM, KubotaM, TominoY, KoideH.Vitamin D metabolism in nephrotic rats. Contrib Nephrol. 1991;90:139–43.
96.
GlassockRJ.Therapy of idiopathic nephrotic syndrome in adults. A conservative or aggressive therapeutic approach?Am J Nephrol. 1993;13:422–8.
97.
OliveroJJ, FrommerJP, GonzalezJM.Medical nephrectomy: the last resort for intractable complications of the nephrotic syndrome. Am J Kidney Dis. 1993;21:260–3.
98.
NiaudetP, HabibR.Cyclosporine in the treatment of idiopathic nephrosis. J Am Soc Nephrol. 1994;5:1049–56.
99.
HawsRM, BaumM.Efficacy of albumin and diuretic therapy in children with nephrotic syndrome. Pediatrics. 1993;91:1142–6.
100.
CaromeMA, MooreJJr. Nephrotic syndrome in adults. A diag-nostic and management challenge. Postgrad Med. 1992;92:209–18.
101.
RuggeriM, MilanM, La GrecaG, CastamanG, RodeghieroA.Adult patients with the nephrotic syndrome: really at risk for deep venous thromboembolism? Report of a series and review of the litera-ture. Haematologica. 1993;78:47–51.
